Cannabis drove me to hallucinate. It must never be legalised – PressReader

✦ New
CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely.
⚒ Cannabis News  |  CED Clinic
PsychosisThcMental HealthRisk AssessmentPatient Safety
Why This Matters

Personal anecdotes about adverse cannabis experiences, while subjectively meaningful, require clinical contextualization to inform evidence-based practice. Understanding the spectrum of cannabis-induced psychotic symptoms helps clinicians counsel patients about risk factors and provide appropriate screening.

Clinical Summary

Cannabis-induced hallucinations represent a recognized adverse effect that can occur with acute intoxication or in vulnerable populations. The mechanism likely involves THC’s agonism at CB1 receptors in brain regions governing perception and reality testing. Risk factors include high-potency products, predisposition to psychotic disorders, adolescent use, and individual genetic vulnerability. Most cannabis-induced perceptual disturbances resolve with cessation, though they may unmask underlying psychiatric conditions in susceptible individuals.

Dr. Caplan’s Take

“Individual adverse experiences deserve clinical attention, but they don’t constitute epidemiological evidence for policy decisions. As clinicians, we need to distinguish between cannabis triggering psychosis in vulnerable patients versus causing it de novo in healthy individuals.”

Clinical Perspective
🧠 Clinicians should screen for personal or family history of psychotic disorders before cannabis recommendations and counsel patients about dose-dependent risks. High-THC products pose greater risk for perceptual disturbances than balanced THC:CBD formulations. Patients reporting any psychotic symptoms with cannabis use require immediate evaluation and cessation counseling.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

FAQ

What is the connection between THC and psychosis risk?

THC, the psychoactive component in cannabis, has been associated with increased risk of psychotic episodes, particularly in vulnerable individuals. This clinical finding is considered of notable interest for mental health monitoring and assessment.

Who should be most concerned about cannabis-related psychosis risks?

Individuals with existing mental health conditions, family history of psychosis, or those using high-THC cannabis products should exercise particular caution. Young adults and adolescents may also face heightened vulnerability to these effects.

How should clinicians assess cannabis-related psychosis risk?

Healthcare providers should conduct thorough risk assessments that include patient history, family mental health background, and current cannabis use patterns. Regular monitoring and screening tools can help identify early warning signs.

What makes this clinical finding particularly noteworthy?

This research represents emerging findings that warrant close monitoring by healthcare professionals. The clinical relevance rating suggests these developments could influence future treatment protocols and patient care guidelines.

What should patients know about cannabis and mental health?

Patients should be aware that cannabis use, particularly high-THC products, may impact mental health in ways that are still being studied. Open communication with healthcare providers about cannabis use is essential for proper risk assessment and care.






{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Cannabis drove me to hallucinate. It must never be legalised – PressReader”, “url”: “https://www.pressreader.com/uk/daily-mail/20260402/282050513613566”, “datePublished”: “2026-04-02T10:29:33Z”, “about”: “cannabis drove me hallucinate must never”}